Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, HEALTH

CNL Launches Program to Accelerate the Development of Targeted Radiopharmaceuticals in Canada


CHALK RIVER, Ontario, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, is pleased to announce that it has issued a call for proposals for a new ?health stream' within its Canadian Nuclear Research Initiative (CNRI). The new program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through collaborative research projects related to health sciences, radiobiology and medical isotope development, by providing access to the world-class laboratories and research capabilities at the Chalk River Laboratories campus.

Launched in 2019, the CNRI program was originally established by CNL to advance the deployment of small modular reactor (SMRs) and advanced reactor designs. The ongoing interest in the program has led CNL to expand CNRI into health sciences, another key area of expertise, allowing participants to gain access to the company's unique facilities and personnel in order to conduct research in partnership with CNL.

"With over one billion medical treatments conducted using isotopes produced at the Chalk River Laboratories, CNL's work has touched the lives of people all around the world," commented Joe McBrearty, CNL's President and CEO. "Today, we continue to pursue this mission as a full-service nuclear laboratory with the capability to perform cutting-edge pharmaceutical development, along with a wide range of radiochemical analyses. Through the expanded CNRI program, we hope to better leverage our resources to help people who suffer from a wide range of medical issues, with a key focus on cancer treatment."

For the program's first intake, research proposals must align with topics that include targeted delivery systems, toxicology and pre-clinical evaluation. Once a technical review of each proposal is completed, CNL will work with the proponent to develop a plan to establish the scope, budget, and deliverables for the project. CNL will complete a final evaluation of the proposed project plans before making the final selection and approval of successful applicants. The deadline for submissions is January 15, 2022, and projects will be selected in the spring of 2022.

As a world leader in medical isotopes and related research for more than 70 years, CNL has helped pioneer the use of Cobalt-60 radiation therapy for the treatment of cancer, and served as a major producer of the world's supply of Molybdenum-99, which is used in diagnostic procedures. CNL now maintains diverse capabilities in areas of health and dosimetry, including pre-clinical animal studies, isotope production and processing, in vitro drug evaluation, targeted radionuclide therapies, ISO-accredited analytical chemistry services and waste management solutions.

"The CNRI program has been incredibly successful for the development of SMRs and other advanced reactor technologies, and it encouraged us to apply this collaborative model to other areas of our research," commented Dr. Jeff Griffin, CNL's Vice-President of Science & Technology. "We believe there is an unmet need for organizations that are pursuing radiopharmaceutical discovery, toxicology and pre-clinical efficacy research, and this program can serve as a vehicle to advance innovative solutions in these areas."

Outside of CNRI, CNL is working to establish itself as an international hub in the research, development and supply of next-generation medical isotopes and radiopharmaceuticals, including Actinium-225, a rare isotope that shows great promise as the basis for new, cutting-edge cancer therapies. As part of those efforts, CNL recently signed a Memorandum of Understanding with ITM Isotope Technologies Munich SE to explore the development and industrial-scale production of Actinium-225.

To learn more about CNL and its work in health sciences, please visit www.cnl.ca/health. For more information on the CNRI Health Stream, including submission guidelines and details, please visit www.cnl.ca/cnri-health.

About CNL
Canadian Nuclear Laboratories is a world leader in nuclear science and technology, offering unique capabilities and solutions across a wide range of industries. Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defence, security and life sciences, we provide solutions to keep these sectors competitive internationally.

With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced with a strong safety culture underscores every activity.

For more information on the complete range of Canadian Nuclear Laboratories services, please visit www.cnl.ca or contact communications@cnl.ca.

CNL Contact:
Patrick Quinn
Director, Corporate Communications
Phone: 1-866-886-2325
Email: communications@cnl.ca

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/869ef61d-4a19-4c86-93d9-47ca287adbd3



These press releases may also interest you

at 14:01
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that a study conducted in collaboration with the European Molecular Biology Laboratory (EMBL) and published as the cover story of the January 21st...

at 14:00
Dialogue Health Technologies Inc. ("Dialogue" or the "Company"), Canada's premier health and wellness virtual healthcare platform, announced today that co-founder and Chief Product Officer Anna Chif has decided to leave the organization for family...

at 14:00
Link-age Solutions, the group purchasing organization (GPO) of the three interconnected companies of Link-age, today announced a new partnership with UNITED Medical Supply Company. UNITED is a Brunswick, Ohio-based company delivering high-quality...

at 14:00
Advancing practice, care, and service standards across the U.S., Avanti Equine Veterinary Partners vaulted into 2022 with two new partnerships. The veterinary network strives to contribute to the greater good, building on its vision of a national hub...

at 14:00
An equine veterinary practice network promoting better practice, care, and service standards all over the country, Avanti Equine Veterinary Partners closed the year enthusiastically. In a second of two visionary, dynamic partnerships, the national...

at 13:58
In response to the significant risks and uncertainties presented by the spread of the Omicron variant in Canada, Indigenous Services Canada (ISC) continues to support Indigenous communities in their response to COVID-19. Vaccinations Vaccination is...



News published on 25 november 2021 at 15:00 and distributed by: